Dr. Patel on the FDA Approval of Durvalumab in NSCLC

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non—small cell lung cancer (NSCLC).

Related Content:

University of Chicago Medicine Comprehensive Cancer CenterOncLive TVImmuno-OncologyLung CancerImmunotherapy in Lung Cancer
OncLive’s September Roundup of Key FDA Approvals in Oncology
Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC